| 从PPA事件认识上市药品不良反应监测的重要性 |
| |
| 引用本文： | 赵树进,袁进.从PPA事件认识上市药品不良反应监测的重要性[J].中国药房,2001,12(9):551-552. |
| |
| 作者姓名： | 赵树进 袁进 |
| |
| 作者单位： | 广州军区广州总医院药学部,广州市,510010 |
| |
| 摘 要： | 目的：由ＰＰＡ事件认识上市后药品不良反应监测的重要性 方法：参考文献及浏览相关网站，综述上市后药品不良反应监测的重要性、建主健全上市药物评价机制及ＡＤＲ监测体系的意义，比较几种：ＡＤＲ监测方法及其注意事项，并对加强ＡＤＲ监测工作提出几点建议 结果与结论：建立健全上市后药物评价机制和上市后药品不良及应监测制度，能有效防止药物不良反应的发生和蔓延
|
| 关 键 词： | PPA事件 药品不良反应监测 药源性疾病 |
| 文章编号： | 1001-0408(2001)09-0551-02 |
| 修稿时间： | 2001年4月20日 |
Recognizing the Importance of ADR Monitoring of Drugs Available on the Market From PPA Event |
| |
| Abstract: | AIM: To recognize the importance of ADR monitoring of drugs available on the market from PPA Event. MET- HODS: With reviewing relevant literatures and scanning relevant network stations. we summarlzed the importance of moni- toring ADR of drugs available on the market and signiticance of creating a perfect evaluation mechanisms and systems of ADR monitoring for those drugs. and analysed several method of ADR monitoring and points for attention Finally. we gave several suggestions about enhancing ADR monitoring .RESULTS& CONCLUSION:ADR events can be effectively pre- vented by perfect evaluation mechanisms and ADR monitoring systems of drugs available on the market. |
| |
| Keywords: | PPA Event ADR monitoring drug -induced disease |
| 本文献已被 维普 万方数据 等数据库收录！ |
